Caris Life Sciences Announces Presentations at AACR 2017 Annual Meeting Demonstrating the Broad Capabilities of ADAPT Biotargeting System

Caris’ Novel Profiling Platform Facilitates a Deeper Understanding of Molecular Complexes to Support Drug Development and Advance Precision Medicine
IRVING, Texas, Mar. 21, 2017 Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced four abstracts that will be presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting on April 1-5 in Washington, D.C. The broad capabilities of the company’s ADAPT Biotargeting System include therapeutic discovery and development, fixed tissue based companion diagnostics, blood-based cancer screening and biomarker identification (proteins and nucleic acids).
“The ADAPT Biotargeting System is a powerful, novel platform to profile biological samples on a systems-wide scale through the use of highly diverse libraries of single-stranded oligodeoxynucleotide (ssODNs) aptamers that bind to individual and multi-component targets,” said David Spetzler, Ph.D., M.B.A., President and Chief Scientific Officer of Caris Life Sciences. “These abstracts show very clearly that the ADAPT Biotargeting System can address a broad range of important needs, including biomarker discovery (abst. 2214), diagnostics (abst. 2754) and drug lead discovery (abst. 2469).  Along with Caris’ other leading edge capabilities, such as deep sequencing of circulating nucleic acids (abst. 4437), the ADAPT Biotargeting System enables us to examine and understand complex biological networks underlying healthy and diseased states.  We believe this platform can dramatically accelerate precision medicine.”
AACR Abstract Summaries
Abstract 2214 / Poster 13: Adaptive Dynamic Artificial Polyligand Targeting (ADAPT): A Method to Identify Exosomal Proteins from a Prostate Cancer Cell Line
Summary: ADAPT was used to identify cancer-associated proteins expressed on exosomes. The platform can be used across multiple cancer types for biomarker discovery.
Date:                   April 3, 2017
Time:                   1:00 – 5:00 p.m. EDT
Location:           Section 9
Abstract 2469 / Poster 26: The B-cell Lymphoma Specific Aptamer 10.36 Binds a Ribonucleoprotein Complex on the Cell Surface of Cancer Cells
Summary: A specific DNA aptamer was identified as a potential targeted therapy to treat Myc expressing malignancies.
Date:                     April 3, 2017
Time:                     1:00 – 5:00 p.m. EDT
Location:            Section 18
Abstract 2754 / Poster 24: A novel liquid biopsy method for development of aptamer libraries that bind blood plasma exosomes from breast cancer patients
Summary: ADAPT was used to identify binding signatures in plasma exosomes that distinguish breast cancer patients from healthy controls.
Date:                     April 3, 2017
Time:                     1:00 – 5:00 p.m. EDT
Location:            Section 30
Abstract 4437 / Poster 15: Small non-coding RNA profiling from prostate cancer plasma by deep sequencing
Summary: High-depth expression profiling of circulating small RNAs revealed signatures associated with prostate cancer.
Date:                     April 4, 2017
Time:                     1:00 – 5:00 p.m. EDT
Location:            Section 18
About Caris Life Sciences®
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company’s ADAPT Biotargeting System is a revolutionary and unbiased profiling platform with applications across therapy development, drug delivery, advanced diagnostics and disease monitoring. Currently being developed for cancer and other complex diseases, the ADAPT Biotargeting System is able to simultaneously measure millions of molecular interactions within complex biological systems in their natural state(s). Caris also offers comprehensive tumor profiling services through its patented and proprietary product, Caris Molecular Intelligence® (CMI). With more than 110,000 clinical cases, CMI provides oncologists with the most clinically actionable treatment options available to personalize cancer care today. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe and other international markets. To learn more, please visit
Media Inquiries:
The Ruth Group
Kirsten Thomas / Joanna Zimmerman /
Tel: +1-508-280-6592 / +1-646-536-7006
Caris Life Sciences Media Relations & Corporate Affairs
Contact Caris Media Relations